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Abstract Women with pulmonary hypertension have a high
risk of morbidity and mortality during pregnancy. The
inability to increase cardiac output leads to heart failure while
further risks are introduced with hypercoagulability and
decrease in systemic vascular resistance. There is no proof
that new advanced therapies for pulmonary hypertension
decrease the risk, though some promising results have been
reported. However, pregnancy should still be regarded as
contraindicated in women with pulmonary hypertension.
When pregnancy occurs and termination is declined, preg-
nancy and delivery should be managed by multidisciplinary
services with experience in the management of both pulmo-
nary hypertension and high-risk pregnancies.
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Introduction
Pulmonary hypertension is a rare disorder that can be
present in women of child-bearing age. During pregnancy it
is associated with high morbidity and mortality in all
defined clinical groups of pulmonary hypertension
(Table 1). Therefore, pulmonary hypertension is regarded
a contraindication for pregnancy [1–4]. However, some-
times women become pregnant despite being advised
against pregnancy, or pulmonary hypertension is newly
diagnosed during pregnancy. These women are usually
advised to terminate the pregnancy even though termination
itself is also associated with maternal risks. Some women do
not regard termination as an acceptable option and carry on
with their pregnancy. This special article discusses the
definition, classification, pathophysiology and clinical features
of pulmonary hypertension during pregnancy, it reviews the
literature on outcome and covers the management of pregnan-
cy in women with pulmonary hypertension, including the
effects of advanced anti-pulmonary hypertension therapies.
Definition and classification
Pulmonary hypertension is defined as an increase in mean
pulmonary arterial pressure (mPAP) ≥25 mmHg at rest as
assessed by right heart catheterisation [2]. It can be present in
multiple clinical conditions. The clinical classification of
pulmonary hypertension is summarised in Table 1 [2].
Haemodynamically, group 1, 3, 4, and 5 are characterised
by a pulmonary wedge pressure <15 mmHg and are referred
to as pre-capillary pulmonary hypertension, while patients in
group 2 have postcapillary pulmonary hypertension with a
pulmonary wedge pressure >15 mmHg. The histopathology
differs between the clinical groups and can include medial
hypertrophy, intimal proliferation, fibrosis, thrombotic
lesions and venous thickening. Complex plexiform lesions
are only present in group 1 (pulmonary arterial hyperten-
sion). Vasoconstriction, obstruction, vascular remodelling
and endothelial dysfunction contribute to the increase in
pulmonary vascular resistance [2, 5].
Pathophysiology related to pregnancy
The normal physiological changes of pregnancy are
poorly tolerated by women with pulmonary hypertension.
Pregnancy is associated with increased plasma volume and
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decreased systemic vascular resistance, both resulting in an
increase in cardiac output. In healthy women a decrease in
pulmonary vascular resistance accommodates the requirements
for increased cardiac output. In women with pulmonary
hypertension, pulmonary vascular disease prevents the fall in
pulmonary vascular resistance, leading to a rise in pulmonary
artery pressure with increased cardiac output. Ultimately, the
necessary increase in cardiac output can not be achieved
resulting in right heart failure. The leftward shift of the
interventricular septum increases, impairing diastolic filling of
the left ventricle and further compromising cardiac output.
Moreover, the hypercoagulability of pregnancy increases the
risk of pulmonary emboli and pulmonary arterial thrombosis.
Paradoxical emboli are a risk in women with a patent foramen
ovale or Eisenmenger syndrome. Women with Eisenmenger
syndrome are at particular risk of increased right-to-left
shunting due to the decrease in systemic vascular resistance,
which results in increased hypoxia, thus aggravating pulmonary
vasoconstriction and right heart failure [5, 6]. Hypoxia can also
lead to syncope and sudden death in this group of patients.
During labour and delivery the risk of complications
increases due to volume shifts resulting from blood loss and
uterus contractions, vasovagal reaction to pain, acidosis and
hypercarbia leading to a further increase in pulmonary
vascular resistance, and an increased risk of thromboem-
bolic complications.
Clinical features and diagnosis
Fatigue and exertional dyspnoea are the most frequent
presenting symptoms. They are due to reduced cardiac
output and impaired oxygen transport. Since these symp-
toms also occur in healthy pregnant women, the diagnosis
during pregnancy can be delayed. Usually the symptoms
aggravate during the course of pregnancy and dyspnoea can
occur at rest. Chest pain is often present and reflects right
ventricular ischaemia. Syncope can result from low cardiac
output. Several signs of right heart failure, such as
hepatomegaly, ascites, and ankle oedema, may be hard to
identify during pregnancy or resemble normal pregnancy.
Elevated jugular venous pressure and a loud pulmonary
component of the second heart sound are useful signs that
point to the diagnosis. Echocardiography will usually reveal
the diagnosis. The threshold to perform echocardiography
should be low during pregnancy in women with dyspnoea
[1]. Right heart catheterisation is required to confirm the
diagnosis and gives useful additional information on
pulmonary vascular resistance and cardiac output. It can
be performed with relatively low foetal risk since radiation
can be avoided. During pregnancy it should be reserved for
women in whom the results have therapeutic consequences,
because of the associated risks of thromboembolism and
infection. Functional capacity needs to be evaluated (New
York Heart Association or World Health Organization
functional class [2]) and exercise capacity can be assessed
with an un-encouraged six-minute walking test.
Prognosis of pregnancy in women with pulmonary
hypertension
In two large series identifying predictors of maternal
cardiac complications during pregnancy in women with
Table 1 Summarised clinical
classification of pulmonary
hypertension
1. Pulmonary arterial hypertension
1.1 Idiopathic
1.2 Heritable
1.3 Drugs and toxins induced
1.4 Associated with
1.4.1 Connective tissue diseases
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic hemolytic anaemia
1.5 Persistent pulmonary hypertension of the newborn
1′ Pulmonary veno-occlusive disease / pulmonary capillary haemangiomatosis
2. Pulmonary hypertension due to left heart disease (systolic or diastolic dysfunction, valvular disease)
3. Pulmonary hypertension due to lung diseases and/or hypoxia (such as chronic obstructive pulmonary
disease, interstitial lung diseases, and others)
4. Chronic thrombo-embolic pulmonary hypertension
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms (such as hematological
disorders, systemic disorders, metabolic disorders and others)
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heart disease, pulmonary hypertension did not emerge as a
predictor of adverse outcome [7, 8]. This is probably due to
low prevalence since women with pulmonary hypertension
are generally advised against pregnancy. Based on disease-
specific literature, there is no doubt that pulmonary
hypertension is associated with severe maternal complica-
tions and high mortality. Two systematic literature reviews
have described the outcome of pregnancy in women with
pulmonary hypertension, covering a total period of almost
30 years and comprising 198 pregnancies [9, 10]. The
mortality of women with Eisenmenger syndrome (N=102)
was 36% in the first review (1978–1996) and 28% in the
second review (1997–2007). Most women died in the first
month after delivery and the main causes of death were
heart failure and sudden death, while pulmonary thrombo-
embolism was another frequent cause. In women with
idiopathic pulmonary hypertension (N=56) mortality was
30% in the first and 17% in the second review. Again most
women died after delivery and heart failure was an
important cause of mortality. Women with other causes of
pulmonary hypertension (N=40) had a mortality of 56%
and 33% respectively. Nearly all fatalities occurred early
post-partum and death was mainly due to heart failure while
sudden death and thromboembolism also contributed. Total
mortality was significantly higher in the earlier period
(1978–1996) compared with the last 10 years (1997–2007),
38% versus 25% (p=0.047). However, since many case
reports or very small series were included in the reviews,
publication bias can not be excluded. In the first review
(1978–1996), late diagnosis of pulmonary hypertension
(p=0.002, odds ratio 5.4) and late hospital admission (p=
0.001, odds ratio 1.1 per week of pregnancy) were
independent predictors of maternal mortality. In the
second review (1997–2007), primigravidae and women
who received general anaesthesia at delivery had a higher
risk of death. Women with previous pregnancies may have
had a lower risk because they had less severe disease,
since they have already survived a pregnancy. The higher
risk for women who had general anaesthesia may be due
to the inherent risks of general anaesthesia, or because
general anaesthesia was more often applied in women with
a more grave clinical condition [10].
It is not known if women with lower pulmonary
pressures and resistance are at lower risk. Systolic or
mean pulmonary artery pressures did not predict
mortality in either of the reviews, but this is possibly
explained by missing data. In the first review (1978–
1996) diastolic pulmonary artery pressure was a univar-
iate risk factor for adverse outcome. In both reviews,
the majority of women who died had severe pulmonary
hypertension, but also some women with mild or
moderate pulmonary hypertension deteriorated. A safe
cut-off value is not known [1, 2, 9, 10].
In the period covered by the second review, advanced
therapy for pulmonary hypertension was becoming increas-
ingly available, but though a significant percentage of
women were treated with NO or prostacyclin analogues, the
institution of advanced therapy did not predict a better
outcome. The authors comment that advanced therapy
was in most cases commenced late in the course of the
disease, when patients were unstable or had refractory
heart failure [10], and that an earlier start of these
therapies will possibly improve outcome. Until recently,
no evidence concerning this subject was available. In
2010 a single-centre series of 10 consecutive pregnan-
cies during 2002–2009 reported improved outcomes. A
multiprofessional approach was applied to all women,
with early institution of targeted therapy (nebulised
prostanoid therapy, changing to intravenous prostanoid
when clinical deterioration or insufficient response
occurred). Planned caesarean delivery with epidural or
combined epidural/spinal anaesthesia was performed at
34 weeks, or earlier when clinical deterioration occurred.
Most women received therapeutic or prophylactic anticoagu-
lation therapy. All 10 pregnancies resulted in live births, and
nomaternal mortality occurred during pregnancy or early after
delivery. One woman died 4 weeks after delivery, after
stopping her therapy at home and declining hospital admission
when she deteriorated. This series is small, but the
results are promising. The authors state that the risk of
pregnancy remains high and despite their results,
women with pulmonary hypertension should be advised
against pregnancy and when they become pregnant,
termination should be offered [11.]
Neonatal outcome is also compromised in women with
pulmonary hypertension. The rate of premature labour and
premature delivery is high. Offspring mortality occurs in
about 10%, and seems higher in Eisenmenger syndrome [9,
10, 12]. In Eisenmenger syndrome, there is also a high
percentage of small for gestational age children [12].
Management of pregnancy and delivery
Women with pulmonary hypertension should be advised
against pregnancy [1–4]. Adequate contraception should be
installed. Barrier methods are safe but not sufficiently
effective. Low-dose combined oral contraceptives contain-
ing ethinyl oestradiol are not suitable for women with
pulmonary hypertension since they are thrombogenic.
Progesterone-only pills or dermal implants can be used.
Endothelin receptor antagonists such as bosentan can
reduce the efficacy of oral contraceptives.
The levonorgestrel-releasing intra-uterine device is very
effective and safe. Vasovagal reactions can, however, occur
during implantation and may be poorly tolerated; therefore,
506 Neth Heart J (2011) 19:504–508
women with pulmonary hypertension should have these
devices implanted in hospital [1–3].
When pregnancy occurs, termination should be offered
even if the woman is in a good clinical condition.
Pregnancy termination is a high-risk procedure and it
should be performed in an experienced centre [1, 2].
When the woman chooses to continue pregnancy, it
is important that she is managed by a multidisciplinary
team in a centre licensed for the treatment of pulmonary
hypertension patients. The team should include a
pulmonary hypertension specialist, a cardiologist, obste-
trician and anaesthetist specialised in managing high-
risk pregnancies, and a neonatologist [5, 6]. The woman
must be followed at least monthly. The cardiac demands
should be minimised by rest and a low salt diet. To avoid
caval vein compression, the patient should lie in the
lateral position. Hospital admission in the second
trimester is often advised, though its benefit is unproven
and a satisfactory outcome of pregnancy has been
described when women were followed on an outpatient
basis [1, 5, 6, 11, 13]. Oxygen should be given when
hypoxaemia is present. Anticoagulation therapy should
be continued when there is an established indication
outside pregnancy. It should, however, be considered on
an individual basis in other women, since there may be
bleeding risk, for example in women with Eisenmenger
syndrome or portal hypertension. When therapeutic
anticoagulation therapy is given, it is mandatory that
the anticoagulation effect is monitored carefully and
frequently, since dose requirements change during
pregnancy with increase in plasma volume and glomer-
ular filtration rate [1].
When heart failure occurs, diuretics are the appropriate
therapy, preferably furosemide. Spironolactone is contra-
indicated because of anti-androgenic effects.
The ESC guidelines on the management of pregnant
women with heart disease advise that women who are on
drug therapy for pulmonary hypertension continue this
therapy during pregnancy [1]. Since bosentan has terato-
genic effects, patients should be informed about the foetal
risks, and substitution with other targeted drugs is often
advised [1, 6, 11]. It is probably beneficial to start advanced
therapy with prostacyclin analogues or sildenafil early
during pregnancy [6, 11].
A timely delivery plan should be constructed and be
available to all team members [14]. The best mode of
delivery is a matter of debate. Vaginal delivery is associated
with volume changes during contractions which poses a
problem in women with pulmonary hypertension since they
have limited capability to increase their cardiac output.
Moreover, pushing can have adverse haemodynamic
effects. Planned caesarean delivery may therefore be a
better choice, though vaginal delivery is not considered
absolutely contraindicated [1]. In many cases vaginal
delivery will not be an option because early delivery is
often necessary. When caesarean section is performed,
general anaesthesia has several disadvantages that should
be taken into account. These include cardiodepression by
volatile agents, and increase of pulmonary vascular resistance
during intubation and positive pressure ventilation. A careful
combined epidural and low-dose spinal anaesthesia avoids
vasodilatation. It can be safely applied by an experienced
anaesthetist and is probably the best option. During delivery
haemodynamic monitoring of arterial and central venous
pressure is advised. Pulmonary artery pressure monitoring
probably has more risks than advantages [1, 5, 6, 11, 13].
Hospital observation is necessary until at least 2 weeks after
delivery [13].
Conclusion
Pulmonary hypertension is associated with high mortality and
morbidity risks for the mother. The risk is increased in all
groups of pulmonary hypertension (1 to 5). Although women
with severe pulmonary hypertension seem to be at higher risk,
a safe cut-off value is not known. Pregnancy is therefore
contraindicated, but if a woman chooses to continue
pregnancy, multidisciplinary care in highly specialised
services is mandatory. New targeted anti-pulmonary
hypertension therapy may decrease the risk.
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